STRATA Skin Sciences closes $2.42mln registered direct offering.

STRATA Skin Sciences has closed a $2.42 million registered direct offering, selling 1,097,547 shares of common stock at $2.204 per share. Ladenburg Thalmann & Co. Inc. acted as exclusive placement agent for the offering. The gross proceeds from the offering will be used to support the company's operations and product development.

HORSHAM, Pa., Sept. 04, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announced the closing of its previously announced registered direct offering for the issuance and sale of 1,097,547 shares of the Company’s common stock at a per share purchase price of $2.204. Ladenburg Thalmann & Co. Inc. acted as exclusive placement agent for the offering. The closing of the registered direct offering occurred on September 4, 2025. The gross proceeds of the offering, before deducting the placement agent fees and other offering expenses payable by the Company, were approximately $2.42 million [1].

The Company intends to use the net proceeds from the offering for working capital and for general corporate purposes. The securities described above were offered pursuant to a shelf registration statement on Form S-3 (File No. 333-283418), declared effective by the Securities and Exchange Commission (“SEC”) on December 18, 2024. The offering was made only by means of a prospectus supplement filed with the SEC on September 3, 2025, which forms a part of the effective registration statement. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC’s website at http://www.sec.gov or by contacting Ladenburg Thalmann & Co. Inc., Prospectus Department, 640 Fifth Avenue, 4th Floor, New York, New York 10019 or by email at prospectus@ladenburg.com [1].

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC® excimer laser, VTRAC® lamp systems, and the TheraClear®X Acne Therapy System. STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice. For more information, please visit www.strataskinsciences.com [1].

The closing of this offering indicates STRATA’s immediate operational cash needs, as the proceeds are intended for working capital and general corporate purposes. The at-market pricing suggests an attempt to minimize dilution while securing necessary funds. Investors should consider whether this capital raise provides sufficient runway for STRATA’s business needs or whether additional financing might be required in the near future [1].

References:
[1] https://www.stocktitan.net/news/SSKN/strata-skin-sciences-announces-closing-of-2-42-million-registered-75h9plwoqzk8.html